ObjectiveTo investigate the effects of metformin combined with dapagliflozin on blood glucose levels, blood lipid metabolism and body fat content in overweight and obese patients with type 2 diabetes mellitus (T2DM). MethodsA total of 107 overweight and obese T2DM patients who were diagnosed and treated in our department from September 2018 to September 2020 were selected as the research objects, which were divided into two groups by the random number method. The control group was treated with metformin, whereas the observation group was given metformin combined with dapagliflozin treatment, for a six-month treatment course. The changes of blood glucose levels, blood lipid levels and body fat content were compared between the two groups before and after treatment. ResultsBefore treatment, there were no statistically significant differences in blood glucose levels between the two groups (P＞0.05). After 6 months of treatment, the levels of glycosylated hemoglobin (HbA1c), fasting plasma glucose (FPG) and 2 hours postprandial blood glucose (2hPG) of patients in both groups decreased significantly. And the levels mentioned above in the observation group were significantly lower than those in the control group, with statistically significant differences (P＜0.05). Before treatment, there were no statistically significant differences in blood lipid levels between the two groups (P＞0.05). After 6 months of treatment, the levels of total cholesterol (TC), triacylglycerol (TG) and low-density lipoprotein cholesterol (LDL-C) significantly decreased in the two groups, and the levels in the observation group were significantly lower than those in the control group. The levels of high-density lipoprotein cholesterol (HDL-C) in the two groups increased significantly, and the level of the observation group was significantly higher than that of the control group, with a statistically significant difference (P＜0.05). Before treatment, there was no statistically significant difference in body fat content between the two groups (P＞0.05). After 6 months of treatment, the observation group yielded lower levels of the whole-body subcutaneous fat rate, visceral fat content and body fat percentage, whereas higher level of the whole-body muscle rate as compared with the control group, with statistically significant differences (P＜0.05). ConclusionMetformin combined with dapagliflozin can significantly decrease blood glucose levels, improve the condition of blood lipid metabolism and reduce the body fat content in overweight and obese T2DM patients.

无